NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
NorthSea Therapeutics has raised $80.0M in total funding. The most recent round was Series C. The last funding was announced in December 2021.
NorthSea Therapeutics's investors include Novo Holdings, Sofinnova Investments, Forbion Capital Partners, Hercules Capital, Ysios Capital.
NorthSea Therapeutics is headquartered in Naarden, The Netherlands.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
NorthSea Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NorthSea Therapeutics — Funding & Investors." VCBacked, December 17, 2021, https://www.vcbacked.co/company/northsea-therapeutics. Accessed November 11, 2026.
VCBacked. (2021). NorthSea Therapeutics — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/northsea-therapeutics
{{cite web |title=NorthSea Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/northsea-therapeutics |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at NorthSea Therapeutics? Request a listing update